Jupiter Neurosciences, Inc announces a new company name, Jupiter Orphan Therapeutics Inc (NYSE:VO) Inc has announced its new name
- Jupiter Orphan Therapeutics, Inc. announced a new name and rename to Jupiter Neurosciences Inc, and another website, www.jupiterneuroscience.com. The name and the name were chosen to reflect the company's expanded focus to include CNS disorders such as Alzheimer'', traumatic brain injury (TBI), and concussion.
In order to officially name Jupiter Orphan Therapeutics, we're pleased to change the name to Jupiter Neurosciences. This will reflect the wide focus of our focus on CNS disorders, stated Christer Rosn, CEO and Chairman This research has demonstrated strong anti-inflammatory effects with JOTROLTM, and focuses on neurosciences underscores our commitment to addressing larger unmet medical needs.
A unique platform product, JOTROLTM, is designed to deliver a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal problems. JOTROLTM is a safe oral medicine that delivers resveratrol with greater bioavailability than conventional severatrone and has demonstrated if it is possible, in preclinical trials, to
About Jupiter Neurosciences:
Jupiter Neurosciences, Inc. is a clinical-stage drug platform company focused on treating neuroinflammation. Phys. / JOTROLTM (the therapeutic candidate of Jupiter) has potential for a number of central nervous system (CNS) diseases, such as Alzheimer's disease (AD) and traumatic brain injury ( JOTROL's multi-functional effects, such as nuclear factor erythyroid-2 activation and epigenetic mechanisms, could also be used to treat Friedreich' ataxia (FA), Mucopolysacc JOTROLTM is being studied in early stage programs for COVID-19 and amyotrophic lateral sclerosis (ALS). www.jupiterneurosciences.com www:juterneulo
Statements with forward-looking outlooks are forward looking at the future.
These press releases may contain certain statements relating to future results that are forward-looking statements. The Company's actual results and financial condition may differ materially from the anticipated results or financial conditions listed in these forward-looking statements, based on factors such as whether results obtained in preclinical and nonclinic studies and clinical trials All forward-looking statements in this press release are made only after the date of this release, and we do not undertake any obligation to publicly update or correct forward forwardlooking statement to reflect circumstances or events which subsequently occur or of which we here
Contacts: Tiberend Strategic Advisors, Inc. Investor Relations Lisa Sher, Senior Vice President, Investor Relations 970-987-2654 [email protected]
Relations with media relations relations David Schemelia, Senior Vice President, Media 609-468-9325 [email protected] (Signal & E-mail: David syllas.
Ingrid Mezo, Vice-President, Media 646-604-5150 [email protected] Ingred, Mzo Assistant, Director of Presse, 647-605-8150.
SOURCE Jupiter Neurosciences SURCE.